PH12013501158A1 - Calicheamicin derivative-carrier conjugates - Google Patents

Calicheamicin derivative-carrier conjugates

Info

Publication number
PH12013501158A1
PH12013501158A1 PH12013501158A PH12013501158A PH12013501158A1 PH 12013501158 A1 PH12013501158 A1 PH 12013501158A1 PH 12013501158 A PH12013501158 A PH 12013501158A PH 12013501158 A PH12013501158 A PH 12013501158A PH 12013501158 A1 PH12013501158 A1 PH 12013501158A1
Authority
PH
Philippines
Prior art keywords
conjugates
calicheamicin derivative
carrier conjugates
derivative
compositions
Prior art date
Application number
PH12013501158A
Other languages
English (en)
Other versions
PH12013501158B1 (en
Inventor
Kunz Arthur
Moran Justin Keith
Rubino Joseph Thomas
Jain Neera
Vidunas Eugene Joseph
Simpson John Mclean
Robbins Paul David
Merchant Nishith
Dijoseph John Francis
Ruppen Mark Edward
Damle Nitin Krishnaji
Popplewell Andrew George
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013501158(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PH12013501158B1 publication Critical patent/PH12013501158B1/en
Publication of PH12013501158A1 publication Critical patent/PH12013501158A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
PH12013501158A 2002-05-02 2013-06-06 Calicheamicin derivative-carrier conjugates PH12013501158A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37744002P 2002-05-02 2002-05-02
PCT/US2003/013910 WO2003092623A2 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates

Publications (2)

Publication Number Publication Date
PH12013501158B1 PH12013501158B1 (en) 2015-11-09
PH12013501158A1 true PH12013501158A1 (en) 2015-11-09

Family

ID=29401497

Family Applications (2)

Application Number Title Priority Date Filing Date
PH12013501158A PH12013501158A1 (en) 2002-05-02 2013-06-06 Calicheamicin derivative-carrier conjugates
PH12013501159A PH12013501159A1 (en) 2002-05-02 2013-06-06 Calicheamicin derivative-carrier conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12013501159A PH12013501159A1 (en) 2002-05-02 2013-06-06 Calicheamicin derivative-carrier conjugates

Country Status (33)

Country Link
US (6) US8153768B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP2371392B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP5153057B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR101062628B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100482277C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2003231293A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BR122019027966B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2871117A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (3) CR7557A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (4) CY1116634T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK1507556T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP045445A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2545745T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR17C1054I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HUE027590T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL164946A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (3) LT1507556T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00044I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04010792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300903I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO339730B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ573563A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH12013501158A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (5) PL224001B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (3) PT1507556T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (3) RU2422157C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (3) SG187991A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI2371392T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI379693B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA88599C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003092623A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA200409752B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SI2371392T1 (sl) * 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
US9237744B2 (en) * 2004-05-26 2016-01-19 National University Corporation Kagawa University Preservative solution for cells, tissues and organs containing rare sugar and preservative method thereof
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
TW200616662A (en) * 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
AU2006279891B2 (en) 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
US20070160577A1 (en) * 2005-12-06 2007-07-12 Wyeth Interleukin-11 compositions and methods of use
CN101437850B (zh) 2006-03-10 2013-10-09 惠氏公司 抗5t4抗体及其用途
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
PL2041270T3 (pl) 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein
BRPI0716435A2 (pt) 2006-08-21 2014-03-04 Synta Pharmaceuticals Corp Compostos para o tratamento de doenças proliferativas
CN101522219A (zh) * 2006-10-12 2009-09-02 惠氏公司 改变抗体溶液中离子强度以减少乳光/聚集物
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
NZ578064A (en) 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof
WO2008079897A2 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US20080247955A1 (en) * 2007-01-16 2008-10-09 Jun Kuai Inflammation treatment, detection and monitoring via TREM-1
ES2541454T3 (es) 2007-03-02 2015-07-20 Wyeth Llc Uso de cobre y glutamato en cultivos celulares para producción de polipéptidos
ES2686019T3 (es) 2007-05-22 2018-10-16 Wyeth Llc Procedimientos mejorados de fabricación de hidrazidas
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
CA2702555A1 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
EP2231183A2 (en) * 2007-12-21 2010-09-29 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
WO2009080831A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
BRPI0821417A2 (pt) * 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
BRPI0821447A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
EP2242772B1 (en) * 2007-12-26 2014-11-26 Biotest AG Immunoconjugates targeting cd138 and uses thereof
US20090186026A1 (en) * 2008-01-18 2009-07-23 Wyeth Ephrin and eph receptor agonists for modulation of bone formation and resorption
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
FR2930443B1 (fr) 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
MX359706B (es) 2008-04-30 2018-10-08 Immunogen Inc Entrelazadores y sus usos.
SI2437790T1 (sl) * 2009-06-03 2019-07-31 Immunogen, Inc. Konjugacijske metode
EP2533814A2 (en) * 2010-02-11 2012-12-19 Ablynx N.V. Delivery of immunoglobulin variable domains and constructs thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
LT4108671T (lt) 2010-10-01 2025-01-10 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
US8512679B2 (en) * 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
MX339927B (es) 2011-03-29 2016-06-16 Immunogen Inc Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
RU2605289C2 (ru) 2011-08-30 2016-12-20 Астекс Фармасьютикалз, Инк. Состав, набор и фармацевтическая композиция, содержащие производные децитабина, их получение и применение
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RU2663794C2 (ru) 2011-10-21 2018-08-09 Пфайзер Инк. Добавление железа для улучшения культивирования клеток
BR112014013694A2 (pt) 2011-12-08 2017-06-13 Biotest Ag método para tratar uma doença, e, kit
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
BR112014033116B1 (pt) 2012-07-03 2021-12-21 Washington University Anticorpo anti-tau monoclonal isolado
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
SG10201705150RA (en) 2012-12-21 2017-07-28 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
WO2014113203A1 (en) 2013-01-17 2014-07-24 Case Western Reserve University Viral nanoparticle multimers
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112015027474A8 (pt) * 2013-05-02 2018-01-23 Hoffmann La Roche anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
ES2768611T3 (es) * 2013-11-04 2020-06-23 Pfizer Intermedios y procedimientos para sintetizar derivados de calicheamicina
TW201605480A (zh) 2013-11-04 2016-02-16 輝瑞大藥廠 抗ｅｆｎａ４抗體－藥物結合物
AU2014384434B2 (en) 2014-02-28 2016-11-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
ES3005909T3 (en) 2014-03-19 2025-03-17 Pfizer Method of cell culture
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
SG11201610620UA (en) 2014-06-20 2017-01-27 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
CA2967336C (en) 2014-11-07 2023-09-26 Case Western Reserve University Cancer immunotherapy using virus particles
US12465624B2 (en) 2018-05-08 2025-11-11 Case Western Reserve University Cancer immunotherapy using virus particles and immune checkpoint therapy
EP3280454A1 (en) 2015-04-07 2018-02-14 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
BR112017022682A2 (pt) * 2015-04-21 2018-07-10 Abbvie Stemcentrx Llc construções de caliqueamicina e métodos de uso
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US10624975B2 (en) 2015-06-29 2020-04-21 Case Western Reserve University Anticancer drug-containing plant virus particles
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
WO2017011826A1 (en) * 2015-07-16 2017-01-19 Case Western Reserve University Plant virus particles for delivery of antimitotic agents
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3353313B1 (en) 2015-09-23 2024-08-07 Pfizer Inc. Cells and method of cell culture
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
KR102784576B1 (ko) 2016-01-08 2025-03-21 알트루바이오 인코퍼레이티드 사가 항-psgl-1 항체 및 이들의 용도
US20170281758A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
JP7253923B2 (ja) 2016-04-05 2023-04-07 ファイザー・インク 細胞培養プロセス
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
WO2018017985A1 (en) 2016-07-21 2018-01-25 Case Western Reserve University Plant virus or virus-like particle constructs
US12433840B2 (en) 2016-11-03 2025-10-07 Case Western Reserve University Melt processed viral nanoparticle constructs
AU2017354004C1 (en) 2016-11-03 2023-08-31 Case Western Reserve University Melt processed viral nanoparticle constructs
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc mesothelin binding proteins
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
CN111868223A (zh) 2017-09-15 2020-10-30 百时美施贵宝公司 大规模生产目的多肽过程中的在线生物质电容监测
DK3694529T3 (da) 2017-10-13 2024-09-23 Harpoon Therapeutics Inc Trispecifikke proteiner og anvendelsesfremgangsmåder
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US11739301B2 (en) 2017-10-27 2023-08-29 Case Western Reserve University Tymovirus virus and virus-like particles as nanocarriers for imaging and therapeutic agents
WO2019178489A1 (en) 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
HRP20210631T1 (hr) * 2018-05-30 2021-05-28 Abbvie Stemcentrx Llc Konjugati protutijela protiv sez6 s lijekom i postupci upotrebe
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020106886A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
US20220073942A1 (en) 2018-12-06 2022-03-10 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
AU2020221271A1 (en) * 2019-02-13 2021-10-07 Coimmune, Inc. Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
CA3146379A1 (en) * 2019-07-08 2021-01-14 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
WO2021113740A1 (en) * 2019-12-04 2021-06-10 The Research Foundation For The State University Of New York Compositions and methods for reducing off-target toxicity of antibody drug conjugates
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
IL298993A (en) 2020-07-07 2023-02-01 BioNTech SE Therapeutic RNA for HPV positive cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
US20250304911A1 (en) 2022-02-02 2025-10-02 Pfizer Inc. Cysteine prototrophy
CN119855620A (zh) * 2022-09-16 2025-04-18 国立研究开发法人量子科学技术研究开发机构 放射性医药组合物的中间体的制造方法、放射性医药组合物的中间体的纯化用试剂盒
CN120166937A (zh) 2022-10-25 2025-06-17 佩普托米克公司 用于治疗癌症的联合疗法
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
KR20250043317A (ko) * 2023-09-21 2025-03-28 주식회사 피노바이오 운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133528T2 (de) 1990-06-27 2006-09-07 Princeton University Proteinkomplex p53/p90
US5558864A (en) 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5712474A (en) * 1993-09-29 1998-01-27 Canon Kabushiki Kaisha Image processing apparatus for correcting blurring of an image photographed by a video camera
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU740904B2 (en) 1997-03-20 2001-11-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US6183477B1 (en) * 1998-09-04 2001-02-06 Smith & Nephew, Inc. Attachment tool for drill guide
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) * 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
ATE264340T1 (de) * 1999-08-17 2004-04-15 Novo Nordisk Healthcare Ag Stabilisierung von gefriergetrocknetem kuchen
AU7787100A (en) 1999-10-12 2001-04-23 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Improved method for the detection of acid resistant microorganisms in a stool
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SI2371392T1 (sl) 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina

Also Published As

Publication number Publication date
EP1507556B1 (en) 2016-07-27
AU2009202609B2 (en) 2012-07-26
KR20110050753A (ko) 2011-05-16
TWI379693B (en) 2012-12-21
PL224150B1 (pl) 2016-11-30
BR0309868A (pt) 2005-10-18
JP2013163678A (ja) 2013-08-22
JP5441971B2 (ja) 2014-03-12
CN1665532A (zh) 2005-09-07
SG10201700289RA (en) 2017-02-27
PT2371392E (pt) 2015-10-07
EP3127553A1 (en) 2017-02-08
LT3127553T (lt) 2022-04-11
HUS1700038I1 (hu) 2017-11-28
EP2371392B1 (en) 2015-07-08
RU2602878C2 (ru) 2016-11-20
HK1162926A1 (en) 2012-09-07
PT1507556T (pt) 2016-09-28
CY2017035I1 (el) 2018-04-04
PH12013501159B1 (en) 2015-12-02
BR122019027974B1 (pt) 2022-06-14
PL413302A1 (pl) 2016-05-23
JP5153057B2 (ja) 2013-02-27
ES2593304T3 (es) 2016-12-07
HUE057124T4 (hu) 2022-02-28
IL230659A (en) 2016-02-29
PH12013501159A1 (en) 2015-12-02
BRPI0309868B1 (pt) 2020-04-28
EP1507556A2 (en) 2005-02-23
HUE057124T2 (hu) 2022-04-28
KR20050006220A (ko) 2005-01-15
EP2371392A1 (en) 2011-10-05
US8835611B2 (en) 2014-09-16
EP1507556A4 (en) 2009-01-07
PL224844B1 (pl) 2017-02-28
JP2017105801A (ja) 2017-06-15
RU2422157C2 (ru) 2011-06-27
BRPI0309868B8 (pt) 2021-05-25
WO2003092623A3 (en) 2004-03-18
ZA201003874B (en) 2019-12-18
IL164946A (en) 2015-06-30
ES2545745T3 (es) 2015-09-15
PL410218A1 (pl) 2015-03-30
PH12013501158B1 (en) 2015-11-09
CN100482277C (zh) 2009-04-29
LUC00044I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-02-26
SI3127553T1 (sl) 2022-02-28
SG165158A1 (en) 2010-10-28
US8747857B2 (en) 2014-06-10
DK3127553T3 (da) 2022-01-31
US20120213804A1 (en) 2012-08-23
NO20161431A1 (no) 2005-01-25
JP6872376B2 (ja) 2021-05-19
LT1507556T (lt) 2016-10-10
CY1116634T1 (el) 2017-03-15
BR122019027966B8 (pt) 2021-07-27
MXPA04010792A (es) 2005-03-07
LTC2371392I2 (lt) 2019-03-25
JP2012051900A (ja) 2012-03-15
LUC00044I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-11-03
NL300903I2 (nl) 2018-02-08
AU2003231293A1 (en) 2003-11-17
DK1507556T3 (en) 2016-09-12
SG187991A1 (en) 2013-03-28
NO339730B1 (no) 2017-01-23
RU2678818C2 (ru) 2019-02-04
NO344509B1 (no) 2020-01-20
WO2003092623A2 (en) 2003-11-13
US20140235835A1 (en) 2014-08-21
US20180339058A1 (en) 2018-11-29
EP3127553B1 (en) 2021-12-01
PL224001B1 (pl) 2016-11-30
PL410219A1 (pl) 2015-03-30
RU2004135101A (ru) 2005-06-27
PL228741B1 (pl) 2018-05-30
BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-08-09
US20040192900A1 (en) 2004-09-30
CR7557A (es) 2008-10-03
CR20120364A (es) 2012-10-05
KR101062628B1 (ko) 2011-09-07
ES2916174T3 (es) 2022-06-28
JP5756489B2 (ja) 2015-07-29
HUE027590T2 (hu) 2016-11-28
TW201231089A (en) 2012-08-01
CA2483552A1 (en) 2003-11-13
CY1117973T1 (el) 2017-05-17
RU2016141576A (ru) 2018-05-03
TW200404005A (en) 2004-03-16
TWI438010B (zh) 2014-05-21
HK1070825A1 (en) 2005-06-30
RU2602878C3 (ru) 2021-11-24
SI1507556T1 (sl) 2016-10-28
DK2371392T3 (en) 2015-08-31
NO20044663L (no) 2005-01-25
NO2017061I1 (no) 2017-11-21
US8153768B2 (en) 2012-04-10
CY2017035I2 (el) 2018-04-04
FR17C1054I2 (fr) 2019-01-11
HUE030806T2 (hu) 2017-05-29
JP2005524700A (ja) 2005-08-18
CY1124900T1 (el) 2023-01-05
ZA200409752B (en) 2010-08-25
FR17C1054I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-12
US20040082764A1 (en) 2004-04-29
RU2016141576A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-05-03
JP2015061875A (ja) 2015-04-02
CA2871117A1 (en) 2003-11-13
PL374523A1 (en) 2005-10-31
ECSP045445A (es) 2005-01-28
KR101125524B1 (ko) 2012-03-22
PT3127553T (pt) 2022-01-24
PL222725B1 (pl) 2016-08-31
RU2422157C3 (ru) 2021-04-23
SI2371392T1 (sl) 2015-10-30
IL230659A0 (en) 2014-03-31
AU2009202609A1 (en) 2009-07-16
PL411824A1 (pl) 2015-08-17
IL164946A0 (en) 2005-12-18
NZ573563A (en) 2010-10-29
UA88599C2 (ru) 2009-11-10
NZ586071A (en) 2012-02-24
US9351986B2 (en) 2016-05-31
RU2011108928A (ru) 2012-09-20
CR20130390A (es) 2013-11-08
LTPA2017036I1 (lt) 2017-11-27
US20160303252A1 (en) 2016-10-20
BR122019027966B1 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
PH12013501159B1 (en) Calicheamicin derivative-carrier conjugates
WO2005089808A3 (en) Antibody calicheamicin conjugates
IN2012DN00520A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX2022011770A (es) Composicion farmaceutica que contiene un conjugado de anticuerpo-farmaco y uso de la misma.
GB0428394D0 (en) Saccharide conjugate vaccines
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
TR200002299T2 (tr) Epotilon kompozisyonları.
TW200630106A (en) Immunotherapy of autoimmune disorders
WO2001085203A3 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
WO2002100437A3 (en) Ophthalmic compositions comprising hyaluronic acid
NO20020154L (no) Anordning som omfatter flere bokstransportörer for sortering av flate gjenstander
WO2004060317A3 (en) Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
WO2002096367A3 (en) Targeted multivalent macromolecules
WO2023001248A9 (zh) 一种含抗trop2抗体药物偶联物的药物组合物及其用途
TW200635934A (en) Amorphous tacrolimus and preparation thereof
TW202545955A (zh) 亞胺基-蒽環衍生物及方法
ZA202311422B (en) Antibody conjugate comprising anti-p-cadherin antibody and uses thereof
EP1800664B8 (en) Pharmaceutical formulations for parenteral administration comprising epothilone
IL167920A (en) An in vitro cell method to generate covalent ligand between the erythropoietin and poly (ethylene glycol) peptide, such medicinal preparations containing said covalent ligand, and its use in the preparation of drugs to stimulate culture, differentiation, and activation of primary myeloid cells
UA85163C2 (en) Criptoblocking antibodies and use thereof